title: Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B.
abstract: In chronic replicative hepatitis B the significance of mutations in the basic core promoter (BCP), core upstream regulatory sequences (CURS) and negative regulatory element (NRE) for response to interferon (IFN) is unknown. A sequence analysis of the NRE, CURS, BCP, and precore region was performed from sera of 96 patients with chronic replicative hepatitis B (64 hepatitis B e antigen [HBeAg]-positive patients and 32 HBeAg-negative patients) treated with alfa-IFN (IFN-alpha). The overall sustained response (SR) rate to IFN was 30% with no significant difference between HBeAg-positive and HBeAg-negative patients. IFN responsiveness correlated to hepatitis B virus (HBV)-DNA levels, hepatitis B surface antigen (HBsAg) levels, the number of mutations in the complete BCP, especially nucleotide (nt) region 1753 to 1766 and mutations at nt 1762 and 1764. In HBeAg-positive hepatitis, SR to IFN was associated with a high number of mutations in the BCP (P <.04) and nucleotide region 1753 to 1766 (P <.015) as well as mutations at nucleotide 1764 (P <.007). In HBeAg-negative hepatitis, SR to IFN correlated with a low number of mutations in the BCP (P <.04) and nucleotide region 1753 to 1766 (P <.02) and a wild-type sequence at nt 1764 (P <.003). Prediction of IFN response was possible on the basis of nt 1764 in 77% of HBeAg-positive patients and 78% of HBeAg-negative patients. IFN response did not correlate with the occurrence of the 1896 mutation, mutations in the CURS or NRE, disease duration, ethnic origin of the patient, alanine transaminase (ALT) levels and HBV genotype. Our data suggest that HBV genome mutations located within the BCP are determinants of a response to IFN therapy.
authors.affiliation: Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Infectious Diseases, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany. erhardt@uni-duesseldorf.de
authors.forename: A
authors.initials: A
authors.lastname: Erhardt
authors.forename: U
authors.initials: U
authors.lastname: Reineke
authors.forename: D
authors.initials: D
authors.lastname: Blondin
authors.forename: W H
authors.initials: WH
authors.lastname: Gerlich
authors.forename: O
authors.initials: O
authors.lastname: Adams
authors.forename: T
authors.initials: T
authors.lastname: Heintges
authors.forename: C
authors.initials: C
authors.lastname: Niederau
authors.forename: D
authors.initials: D
authors.lastname: Häussinger
mesh_terms: D000328:Adult; D001483:Base Sequence; D005260:Female; D019694:Hepatitis B, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D017421:Sequence Analysis; D014758:Viral Core Proteins / Q000737:chemistry / Q000235:genetics*; D014779:Virus Replication
chemical_list: D014758:Viral Core Proteins; D007372:Interferons